ALX Oncology Holdings ALXO 深 沪
等待开盘 10-13 09:30:00 美东时间
1.26
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.26
- 总市值 1.74亿
- 52周最高 2.66
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.05
- 委 比 0.00%
- 总股本 1.38亿
- 历史最高 117.45
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.404
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease Subgroup analyses support CD47 expression as a predictive biomark...
09-28 20:03
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
ALX Oncology's ASPEN-06 Phase 2 trial demonstrated that evorpacept combined with trastuzumab, ramucirumab, and paclitaxel achieved a 40.3% ORR in HER2-positive advanced gastric or GEJ cancer, compared to 26.6% for control. Among patients with high CD47 expression, ORR increased to 63.6% versus 23.1%. These findings validate CD47 as a predictive biomarker and support ALX Oncology's biomarker-driven strategy. The company remains focused on its Phas...
09-28 12:00
ALX Oncology to Present at Upcoming Investor Conferences in September
ALX Oncology Holdings Inc. announced that its leadership will participate in fireside chats at three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, in Boston; the Cantor Global Healthcare Conference on September 10, 2026, in New York; and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, also in New York. Webcasts of the fireside chats will be available on A...
09-02 12:00
ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 75 percent increase over losses of $(0.44) per share from the same period last year.
08-06 20:39
ALX Oncology GAAP EPS of -$0.13
ALX Oncology press release (ALXO): Q2 GAAP EPS of -$0.13. Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2026, were $153.4 million. The Company believes ...
08-06 20:14
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported Q2 2026 financial results and updates, highlighting progress in clinical trials for evorpacept and ALX2004, strong enrollment momentum, and a strengthened leadership team. The company's cash reserves remain robust, with R&D and G&A expenses decreasing compared to the prior year.
08-06 12:00
ALX Oncology Appoints New Chairman Amid Leadership Changes
The latest announcement is out from ALX Oncology Holdings ( ($ALXO) ). On June ...
07-01 04:39
ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the appointments of Scott Garland as Chairman of the Board of Directors (the "Board") and Mic...
06-30 20:12
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
ALX Oncology Holdings Inc. announced that its leadership will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 5:30 PM ET. The webcast can be accessed via their website or the provided link. ALX Oncology focuses on developing innovative cancer therapies, with its lead candidate, evorpacept, and ALX2004, an EGFR-targeted antibody-drug conjugate, currently in clinical trials.
06-01 12:00
ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 68.75 percent increase over losses of $(0.48) per share
05-08 20:02
